February 27, 2013
11:30 am – 12:30 pm EST

Sponsored by

Simoa Science  

Symposium Course Description: 

Dr. Thomas Joos will provide an overview on array-based assay systems that allow the analysis of hundreds of molecular parameters in a single experiment. Within the last decade protein microarray technologies have achieved robust analytical performance enabling a multitude of parameters to be screened using minimal amounts of sample material. However, the degree of multiplex is limited to approximately 20 analytes per assay. Incompatible assay formats and the inherent problem of antibodies´ cross-reactivity decrease the sensitivity of a multiplex versus a singleplex test. A simple and efficient way to overcome these current limitations of multiplexing sandwich immunoassays will be presented. Biomarker discovery activities will be discussed within the context of the FDA’s critical path initiative and the Europe-based public–private Innovative Medicines Initiative (IMI)

Learning Objective Bullet Points: 

  • Advances and limitations of multiplex immunoassay platforms
  • Understand Single Molecule Array (Simoa) technology and its application for basic, translational and clinical researchers who wish to quantify and validate low abundance protein biomarkers

Who Will Benefit: 

  • Laboratories currently utilizing immunoassays for discovery, preclinical studies and clinical trials that desire the highest sensitivity and precision, the ability to generate data rapidly for increased productivity, and multiplex using small sample volumes
  • Researchers and clinicians specializing in Assay Development, Biomarkers, CNS, Diagnostics, Personalized Medicine, Proteins and Proteomics, Translational Medicine

Program Agenda: 

  • Immunoassays in Multiplex for Biomarker Discovery and Validation
    • Presentation by Dr. Thomas Joos, NMI Natural and Medical Sciences Institute at the University of Tübingen 
  • Introduction to Quanterix Single Molecule Array (Simoa) technology
    • Presentation by Dr. David Duffy, Quanterix Corporation 
  • Q&A (5-10 min)

Speaker Information: 

Thomas JoosThomas O. Joos, Ph.D.
Head of the Biochemistry Department
NMI Natural and Medical Sciences Institute at the University of Tuebingen
Markwiesenstr. 55, 72770
Reutlingen, Germany
+49 7121 51530 844

Dr. Thomas Joos is head of the Biochemistry Department of the NMI Natural and Medical Sciences Institute at the University of Tübingen. Dr. Joos has been with the NMI since 1998, where he has been responsible for protein microarray technology for proteomic re-search and diagnostics. Recently, Dr. Joos joined in a part time position EDI GmbH, Reutlingen, Germany, the german subsidiary of Myriad RBM, Austin, TX, USA, to manage public granted projects.

Prior to joining the NMI, Dr. Joos did his postdoctoral research in the laboratory of Prof. Peter Hausen at the Max-Planck-Institute of Developmental Biology, Department of Cell biology, researching cell-cell and cell-matrix interaction during early embryogenesis of Xenopuslaevis. Dr. Joos studied Biochemistry at the University of Tübingen. He received his Ph.D. degree in 1985 on integrin-∝5 during early embroygenesis of Xenopuslaevis.

Dr. Joos is a member of the editorial board of Drug Discovery Today, Proteomics,Molecular Biotechnology and Expert Review of Proteomics. He is a member of the scientific advisory board of the "Plasma Proteome Institute" Washington, DC, USA and of the “AlbaNova VINNExcellence Centre for Protein Technology (ProNova)” at the Royal Institute ofTechnology, Stockholm, Sweden. Dr. Joos is a member of the SAB of Myriad RBMInc., Austin, TX, USA.

David Duffy, Ph.D.
Vice President, Research
Quanterix Corporation
113 Hartwell Avenue
Lexington, MA 02421